Search research articles
Contact Us
Filters
Showing results (51-60 of 82) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2004
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
John Rinehart, Alex A Adjei, Patricia M Lorusso, et al.
Gastrointestinal Endoscopy
|
January 18, 2012
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study
J Randolph Hecht, James J Farrell, Neil Senzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2021
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
J Randolph Hecht, Sara Lonardi, Johanna Bendell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 6, 2017
Most of the Intended Management Changes After <sup>68</sup>Ga-DOTATATE PET/CT Are Implemented
Jeremie Calais, Johannes Czernin, Matthias Eiber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2022
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Zev A Wainberg, Arun S Singh, Gottfried E Konecny, et al.
NPJ Precision Oncology
|
August 5, 2024
Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities
Ariane Lozac'hmeur, Tyler Danek, Qidi Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2017
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
Efrat Dotan, Steven J Cohen, Alexander N Starodub, et al.
Lancet (London, England)
|
October 23, 2025
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
J Randolph Hecht, Young Suk Park, Josep Tabernero, et al.
BJC Reports
|
February 27, 2025
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
J Randolph Hecht, Jean-Marie Michot, David Bajor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 82) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2004
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
John Rinehart, Alex A Adjei, Patricia M Lorusso, et al.
Gastrointestinal Endoscopy
|
January 18, 2012
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study
J Randolph Hecht, James J Farrell, Neil Senzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2021
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
J Randolph Hecht, Sara Lonardi, Johanna Bendell, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 6, 2017
Most of the Intended Management Changes After <sup>68</sup>Ga-DOTATATE PET/CT Are Implemented
Jeremie Calais, Johannes Czernin, Matthias Eiber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2022
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Zev A Wainberg, Arun S Singh, Gottfried E Konecny, et al.
NPJ Precision Oncology
|
August 5, 2024
Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities
Ariane Lozac'hmeur, Tyler Danek, Qidi Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2017
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
Efrat Dotan, Steven J Cohen, Alexander N Starodub, et al.
Lancet (London, England)
|
October 23, 2025
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
J Randolph Hecht, Young Suk Park, Josep Tabernero, et al.
BJC Reports
|
February 27, 2025
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
J Randolph Hecht, Jean-Marie Michot, David Bajor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
Page
of 9